TAURx Pharmaceuticals Ltd
Receives Frost & Sullivan’s
ASIA-PACIFIC NEUROGENERATIVE
DISEASE MANAGMENT
TECHNOLOGY INNOVATION AWARD

Frost & Sullivan Best Practices Awared 2019

Clinical Trials

LUCIDITY, a new clinical trial examining the effects of LMTX^® in patients with mild Alzheimer’s disease, is now underway.
Find out more

Pioneering Science

The tau tangle pathway is a key driver of Alzheimer’s disease leading to loss of neuronal function, spread of pathology and clinical symptoms. Find out more

About Tau proteins

TauRx’s tau aggregation inhibitors are the outcome of nearly 30 years of research, preclinical and clinical investigations. Find out more

Our products

Through TauRx’s technology platform, the company is continuing to discover and develop new treatments and diagnostic compounds. Find out more

Leading Alzheimer's innovations through pioneering science and research

A leader in Alzheimer's disease research, TauRx's mission is to discover, develop and commercialize innovative products for the diagnosis, treatment and cure of neurodegenerative diseases caused through protein aggregation.

Clinical Trials

Pioneering Science

About Tau proteins

Our products

Lastest news